All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lupus Hub

Brought to you by Scientific Education Support

Scientific Education Support

The Lupus Hub is an independent medical education platform, sponsored by Autolus, Biogen and Biogen MA, Inc. and UCB. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My Lupus Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View lupus content recommended for you

ACR Convergence 2022

Share:

Nov 12, 2022

X post image

28 May 2023

Weekend read!

Are there more sensitive biomarkers for kidney damage in patients with #lupusnephritis compared with proteinuria? Review the data from #ACR22 in our latest article. #SLE

👉 https://t.co/IH141KUhYp
@andreafava @JohnsHopkins

X post image

1 Mar 2023

#ACR22 | 🎧 The Lupus Hub was pleased to speak to Murray Urowitz. We asked, What were the key communications on lupus at ACR 2022?

Listen to the interview here: https://t.co/vuWHtz9rq2
@uoftmedicine

X post image

9 Feb 2023

#ACR22 | Are any of the traditional laboratory markers used in monitoring lupus patients suitable as biomarkers for renal flares? Read this brief summary of a presentation by @gomezg_alvaro.
Click here to find out 👉 https://t.co/P3lGbOG0QR
#lupus

X post image

27 Jan 2023

#ACR22 | @CGArriens presented results from the AURORA studies of voclosporin for #lupus nephritis. 66.4% of patients treated with voclosporin achieved a good renal response.
Read more 👉 https://t.co/3VV2Kmc2xe

X post image

25 Jan 2023

#ACR22 | Kenneth Kalunian discussed the 3-year extension of the TULIP-1 and -2 trials. Mean improvements in SLEDAI-2K were greater in anifrolumab-treated patients vs placebo.
Read more: https://t.co/fBdr9sjAMi
#SLE

X post image

19 Jan 2023

#ACR22 | Read a highly visual summary of the phase II study of deucravacitinib in patients with #SLE from the ACR Convergence 2022.
👉 https://t.co/osvvZnqUSN

X post image

5 Jan 2023

Are there more sensitive biomarkers for kidney damage in patients with #lupusnephritis compared with proteinuria? Review the data from #ACR22 in our latest article. #SLE
👉 https://t.co/IH141KUhYp
@andreafava @JohnsHopkins

X post image

28 Dec 2022

HCQ is associated with increased risk of retinopathy but do lower doses increase the risk of hospitalization in patients with #SLE? See our summary article of Jacquelyn Nestor’s talk at #ACR22 to learn more.
👉 https://t.co/mwPfb6F99i
@MGHrheumatology

X post image

15 Nov 2022

We hope you enjoyed following our live updates and congress coverage.

We covered #ACR22 from Philadelphia, Pennsylvania, as well as virtually.

Keep an eye on our socials for post-congress key points and insights!

#psoriasis #lupus #medicalcongress #rheumatology

X post image

14 Nov 2022

CONGRESS #ACR22 | Marilyn Pike discussed 48 week results from a phase II trial of deucravacitinib in pts with active #SLE. Adverse event rates were similar between DEU and placebo treated pts, with the primary endpoint being met at week 32. #lupus

X post image

14 Nov 2022

CONGRESS #ACR22 | @karen_kc123 discussed concomitant CS use & adherence in adults with ND #SLE (N= 2476). Adherence to biologics was highest. Adherence to antimalarials & immunosuppressants declined with increasing LOT. CS use was 50% in LOT1 and 60% in LOT2 & 3. #lupus

X post image

14 Nov 2022

CONGRESS #ACR22 | Katherine Owen discussed differences in risk alleles in pts with #SLE of East Asian vs European ancestry. Gene expression pathways were found to be different in pts of Asian vs Euro ancestry, and targeting metabolic pathways could be effective for East Asian pts

X post image

14 Nov 2022

CONGRESS #ACR22 | Emma Materne presented a poster about infection risk in pts with #SLE treated with belimumab vs oral immunosuppressants. Pts treated with belimumab were found to have lower severe infection risk, and lower risk for hospitalisation due to infection. #lupus

X post image

14 Nov 2022

CONGRESS #ACR22 | Anca Askanase discusses phase 2b CARE study of cenerimod vs pbo for #SLE. mSLEDAI-2K reduction baseline to 6mo was not significant after type I error correction Exp analysis suggests cenerimod may work in severe disease, or high IFN-1 pts AEs were similar #lupus

X post image

14 Nov 2022

CONGRESS #ACR22 | Jacquelyn Nestor of @MGHMedicine discussed HCQ dose & risk of hospitalization for #SLE flares. Low dose HCQ was associated with increased hospitalizations: adjusted OR = 4.41 (≤5 vs 5 mg/kg/day) and adjusted OR = 3.48 (< 400 vs 400 mg/day). #lupus

X post image

14 Nov 2022

CONGRESS #ACR22 | @CGArriens presents results of long-term safety & efficacy of voclosporin vs ctrl for LN (AURORA2) SAEs were similar (26.7% voc vs 28% pbo). UPCR reductions were maintained.Good renal outcome was achieved by 66.4% voc & 54% ctrl p=0.045. #lupus

X post image

14 Nov 2022

CONGRESS #ACR22 | Kenneth Kalunian: long term safety & efficacy from TULIP-LTE of anifrolumab (ani) vs pbo for #SLE. AEs were similar though deaths in all ani (0.6/100py) were higher than pbo (0.3/100py) & ani resulted in >imp in SLEDAI-2K vs pbo which was maintained. #lupus

X post image

14 Nov 2022

The Lupus Hub will be covering the following sessions today:

▪️ CAR T Cell Treatment of Refractory SLE
▪️ Association of Ultra-processed Food Intake with Risk of SLE in Women
▪️ And more!

Stay tuned for updates throughout the day.
#ACR22 #medicalcongress #rheumatology #lupus

X post image

13 Nov 2022

CONGRESS #ACR22 | @EricFMorand talked about LLDAS & improved outcomes in #SLE. Achievement of LLDAS protected pts with #lupus against damage accrual & flare in a dose dependent manner in both sustained & cumulative time. Steroid free remission protects against flare.

X post image

13 Nov 2022

CONGRESS #ACR22 | @RashmiDhitalMD discusses serious infection related hospitalizations (SIH) by age in #SLE. Hosp rate, LOS & cost similar in pts aged 18-24 (YA) & pts aged 25-49 (LA) with #lupus & higher than controls. Increasing SIH in YA may be driven by increase in septicemia

X post image

13 Nov 2022

CONGRESS #ACR22 | Amita Aggarwal presents retro study of infection in 1354 pts with #SLE. There were major infections in 339 pts, most common bacteria was S aureus. GI involvement & daily steroid dose were associated with infection (HR 2.07-2.75 and 1.43-1.65 respectively) #Lupus

X post image

13 Nov 2022

CONGRESS #ACR22 | @RaisaLomanto discussed how medication co-pay can affect adherence to treatment in #SLE. There was found be an association between higher co-pay and lower rates of adherence, which was not affected by household income. #lupus

X post image

13 Nov 2022

CONGRESS #ACR22 | Rachel Elam presented cross sectional study of sex & racial diffs in adults with #SLE. Of pts included 9-11% were men who had lower educational attainment, & lower confidence in filling in medical forms. Barriers to healthcare utilisation differed by race #Lupus

X post image

13 Nov 2022

CONGRESS #ACR22 | Vivian Kawai presented a poster about disproportionate rates of #SLE in patients with African ancestry. African pts were younger with higher rates of LN. Adverse renal outcomes could not be linked to presence of APOL1B high risk variants. #lupus

X post image

13 Nov 2022

CONGRESS #ACR22 | @andreafava presented a poster about autoantibodies in pts with #lupus nephritis. Pts with LN commonly exhibit autoantibodies against chromatin and dsDNA, which can act as biomarkers of proliferative LN.

X post image

13 Nov 2022

CONGRESS #ACR22 | Daniel Toro-Domínguez presented a poster about MyPROSLE, a workflow that measures molecular portraits of pts with #SLE to support therapeutic decisions. M-score calculations can show how dysregulated a biological pathway is compared to the healthy state. #lupus

X post image

13 Nov 2022

The Lupus Hub will be covering the following sessions today:

▪️ Sex & Racial Differences in SLE Among US Adults
▪️ Medication Co-pay Modifies Treatment
Adherence in pts with SLE
▪️ And more!

Stay tuned for updates throughout the day.
#ACR22 #medicalcongress #rheumatology #lupus

X post image

13 Nov 2022

CONGRESS #ACR22 | Christine Wang presented a retro cohort study of youths with proliferative LN treated with the EuroLupus CYC regimen (65) vs the NIH regimen (97). At 12 months, there was no significant difference in complete renal response after multivariable adjustment #Lupus

X post image

12 Nov 2022

#ACR22 https://t.co/ee4lxeGZAh

X post image

12 Nov 2022

CONGRESS #ACR22 | Tara Tofighi discusses retro analysis of VTE prevalence in LN & risk factors of VTE. 10.4% LN pts developed VTE, 78% had DVT in lower extremity. VTE was associated with Black ethnicity, presence of dsDNA, APLA positivity, SDI & SLEDAI-2K scores #Lupus

X post image

12 Nov 2022

CONGRESS #ACR22 | @gomezg_alvaro presented an analysis from 4 phase III BLISS trials evaluating predictors of renal flares in pts with #SLE. Adjusted modelling found low C3 levels, plasma albumin levels, & proteinuria, at baseline, assoc. with increased risk of renal flare #Lupus

X post image

12 Nov 2022

CONGRESS #ACR22 | Anna Broder presented on cardiac outcomes in patients with LN & ESKD. Patients on hydroxychloroquine alone had lower risk of cardiac complications & infection than pts on corticosteroids alone. Thrombotic complications & all-cause mortality were similar. #Lupus

X post image

12 Nov 2022

The Lupus Hub will be bringing you live updates as we continue our in-person and online coverage of #ACR22.

Sessions covered today:
▪️ Pediatric Rheumatology
▪️ Traditional Laboratory Markers as Predictors of Renal Flare
▪️ And more!

#medicalcongress #rheumatology #lupus

X post image

10 Nov 2022

#ACR22 starts today!

The Lupus Hub is covering ACR virtually and in person.

Keep an eye on our Twitter page for live updates, key insights, and interview coverage.

#medicalcongress #rheumatology #lupus

<span> </span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

ACR Convergence 2022 American College of Rheumatology Convergence

Newsletter

Subscribe to get the best content delivered to your inbox